Brisbane Clinical Trials

The Access Study

The study drug is a biosimilar of an already approved drug used to treat life-threatening diseases of the blood.

8 nights
5 phone calls + 8 visits
  • Study Objective: To evaluate the efficacy and safety of a biosimilar for treating PNH and aHUS.

  • Understanding PNH and aHUS: PNH and aHUS are life-threatening blood diseases that can lead to severe complications.

  • Importance of Biosimilars: Biosimilars provide more affordable treatment options and can prevent medicine shortages.

  • Clinical Trial Details:
  • The trial is designed to offer an alternative to high-cost medications, ensuring wider patient access and affordability
  • An independent ethics committee has approved this clinical trial.
  • Participants will be reimbursed for their time.

Call us on 1800 243 733 to discuss your eligibility today!


Biological Sex Male
Age 18 – 55 years old
Weight 50kg - 95kg
BMI 18 - 30 kg/m²
Medical History No significant medical history
Medication Not taking any medication
Smoking History Non-smoker or light smokers (<5 cigarettes/day)